Trial intelligence / Profile preview

Neoadjuvant SIRT plus capecitabine for operable intrahepatic cholangiocarcinoma

2024-516683-29-00Phase 2Authorised

Sponsor: Centre Eugène Marquis
Start: Feb 2022
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised, open-label trial of capecitabine in intrahepatic cholangiocarcinoma (ICC) and biliary cancer (2 arms), sponsored by Centre Eugène Marquis. Primary endpoints: Adequate surgical margins, Actual resection rate and 5 more. Planned start Feb 2022; status: authorised.

Drugs

capecitabine

Conditions

intrahepatic cholangiocarcinoma (ICC)biliary cancer

Beyond the preview

Go deeper on 2024-516683-29-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-516683-29-00.